Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory

FDA Conditional Acceptance of Lyrfigtu Brand Name

Analysis based on 7 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026

Sentiment
5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA conditional brand-name acceptance is a modest positive milestone for Elevar Therapeutics and its parent HLB Co., Ltd., keeping the lirafugratinib commercialization path on track ahead of the September 25, 2026 PDUFA date. Market reaction is likely muted until the actual approval decision, though a positive outcome could lift HLB shares on the KOSDAQ while a rejection would weigh on the stock.

biopharmaceutical oncology healthcare

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced on September 22, 2026 that the U.S. United States — Food and Drug Administration granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib. The drug is currently under FDA Priority Review as a treatment for patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or other rearrangement. Final acceptance of the brand name will be established upon FDA approval of lirafugratinib. In January 2026, the FDA accepted Elevar's new drug application for lirafugratinib and subsequently granted Priority Review, assigning a Prescription Drug User Fee Act target action date of September 25, 2026. In the Phase 1/2 ReFocus trial, lirafugratinib demonstrated a confirmed objective response rate of 46% and a median duration of response of 11.8 months in patients with the proposed indication. Elevar holds an exclusive license to lirafugratinib from Relay Therapeutics, Inc. for worldwide commercialization. Elevar CEO Dong-Gun Kim called the conditional acceptance another important milestone and said the company is preparing for a potential launch. HLB Co., Ltd. trades on the KOSDAQ, where its stock closed at KRW 31,050.00, down 2.82 percent.

priv
Elevar Therapeutics is the central company in this event, receiving FDA conditional acceptance of the Lyrfigtu brand name for lirafugratinib and preparing for a potential commercial launch. The milestone advances its oncology commercialization effort, though final brand acceptance and approval remain pending.
Importance 95.0 Sentiment 30.0
govactor
The FDA granted conditional acceptance of the Lyrfigtu brand name and is conducting the Priority Review of lirafugratinib with a PDUFA date of September 25, 2026. Its upcoming approval decision is the key catalyst for the event.
Importance 85.0 Sentiment 0.0
stock
HLB Co., Ltd. is the majority owner of Elevar Therapeutics and its KOSDAQ-listed shares are the main market exposure to this event. The brand-name milestone is positive for HLB, but its stock closed down 2.82 percent on the KOSDAQ on the announcement day.
Importance 80.0 Sentiment 20.0
stock
Relay Therapeutics is the licensor of lirafugratinib to Elevar Therapeutics for worldwide commercialization. Progress toward approval could yield milestone or royalty value for Relay, though it is a secondary beneficiary in this event.
Importance 40.0 Sentiment 10.0
exch
The KOSDAQ is the exchange where HLB Co., Ltd. trades, and it recorded HLB's stock closing at KRW 31,050.00, down 2.82 percent on the announcement day. It serves as the venue reflecting market reaction to the event.
Importance 30.0 Sentiment 0.0
cnt
South Korea is the home jurisdiction of HLB Co., Ltd. and the KOSDAQ listing, making it the relevant national market context for the event. The event has limited direct impact on the country itself.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.